PDCD1 and neoplasm: In addition, hyperprogression, a new pattern of disease progression after anti-PD-1/PD-L1 monotherapy, that is associated with elderly age and worse overall survival but not specific tumor types, has been identified in ~9% of cancer patients (232, 233).